MedTrace Logo

Improving Metoclopramide Prescribing Practices at Penn Through a Physician-targeted Intervention

NCT01126034 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 85

Last updated 2015-12-04

No results posted yet for this study

Summary

The investigators hypothesized that:

1\) an intervention targeted at the prescribing physician would increase the rate of a metoclopramide discontinuation among patients prescribed the medication for questionable or unclear indications; and 2) the discontinuation would be durable.

Conditions

  • Gastroesophageal Reflux Disease
  • Diabetic Gastroparesis

Interventions

OTHER

intervention letter

Physicians in the intervention group were mailed a written feedback letter regarding their patients who were prescribed questionable metoclopramide therapy. Non-intervention providers received no letter. The letter consisted of the following components: 1. The name and medical record # of the patients involved 2. Information regarding the metoclopramide prescription: dates, dosage, indication recorded, and the duration of therapy 3. A reminder of the adverse effect of long-term metoclopramide therapy 4. A recommendation to consider having the patient undergo a trial of metoclopramide discontinuation if appropriate, and documentation of a discussion of risk and benefits of metoclopramide therapy with patients 5. A request that the physician document the discontinuation trial in the electronic medical record

Sponsors & Collaborators

Principal Investigators

  • Yu-Xiao Yang, MD, MSCE · University of Pennsylvania

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2008-04-30
Completion
2008-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01126034 on ClinicalTrials.gov